These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 19167603

  • 21. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A, Owens G, Bloudek L, Kori S, Cole A, Chia J.
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [Abstract] [Full Text] [Related]

  • 22. Clinical advances in the preventive treatment of migraine.
    Mannix LK.
    Acta Neurol Taiwan; 2004 Dec; 13(4):158-69. PubMed ID: 15666691
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Determinants of prophylactic migraine therapy in Spain].
    Pascual-Gómez J, Caminero AB, Cano A, Heras-Pérez JA, Leira-Muiño R, García-Ribas G, grupo de investigadores participantes en el estudio PREVENTIA.
    Rev Neurol; 2004 Dec; 45(9):513-8. PubMed ID: 17979079
    [Abstract] [Full Text] [Related]

  • 25. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study).
    Gupta P, Singh S, Goyal V, Shukla G, Behari M.
    Headache; 2007 Mar; 47(3):402-12. PubMed ID: 17371357
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Resource use associated with topiramate in migraine prophylaxis.
    Feliu AL, Rupnow MF, Blount A, Boccuzzi SJ, Vermilyea J.
    Am J Health Syst Pharm; 2007 Jul 15; 64(14):1483-91. PubMed ID: 17617498
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M.
    Headache; 2021 Apr 15; 61(4):590-602. PubMed ID: 33594672
    [Abstract] [Full Text] [Related]

  • 33. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
    McHorney CA, Victor Spain C, Alexander CM, Simmons J.
    Clin Ther; 2009 Nov 15; 31(11):2584-607. PubMed ID: 20110004
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis.
    Afshari D, Rafizadeh S, Rezaei M.
    Int J Neurosci; 2012 Feb 15; 122(2):60-8. PubMed ID: 21950578
    [Abstract] [Full Text] [Related]

  • 38. Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.
    Atasayar G, Eryilmaz IE, Karli N, Egeli U, Zarifoglu M, Cecener G, Taskapilioglu O, Tunca B, Yildirim O, Ak S, Tezcan G, Can FE.
    J Neurol Sci; 2016 Jul 15; 366():149-154. PubMed ID: 27288795
    [Abstract] [Full Text] [Related]

  • 39. The Paediatric migraine disability assessment score is a useful tool for evaluating prophylactic migraine treatment.
    Topcu Y, Hiz Kurul S, Bayram E, Sozmen K, Yis U.
    Acta Paediatr; 2014 Nov 15; 103(11):e484-9. PubMed ID: 25048365
    [Abstract] [Full Text] [Related]

  • 40. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety.
    Winner P, Gendolla A, Stayer C, Wang S, Yuen E, Battisti WP, Nye JS.
    Headache; 2006 Nov 15; 46(10):1503-10. PubMed ID: 17115983
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.